A synthetic peptide modeled after wasp venom protected mice from chemically induced seizures when injected into the brain, but had no effect when given systemically.
Brain injection onlyNOR-1202 protected against seizures only when injected directly into the brain — systemic delivery showed no effect, suggesting it cannot cross the blood-brain barrier
What the researchers found
NOR-1202 showed route-dependent antiepileptic effects. Direct brain injection (intracerebroventricular) protected against pilocarpine-induced generalized seizures and mortality. In the kainic acid model, it improved survival but did not prevent seizures. Systemic administration (subcutaneous or intraperitoneal) showed no antiepileptic activity, suggesting the peptide cannot cross the blood-brain barrier. In a chronic temporal lobe epilepsy model, NOR-1202 did not significantly reduce spontaneous recurrent seizures.
Why it matters
Current antiepileptic drugs often fail for temporal lobe epilepsy and cause significant side effects. Venom-derived peptides represent a novel class of potential neurological therapeutics. While NOR-1202's inability to work systemically limits its current utility, understanding its brain-level mechanism could guide development of modified versions that cross the blood-brain barrier.
The numbers in context
- NOR-1202: analog of occidentalin-1202 (from Polybia occidentalis wasp venom)
- Acute pilocarpine model: brain injection protected against seizures and mortality
- Kainic acid model: brain injection improved survival but did not prevent seizures
- Chronic TLE model: no significant reduction in spontaneous recurrent seizures
- Systemic (SC or IP) injection: no antiepileptic activity
How the study worked
Animal study using male mice in three seizure models: acute pilocarpine-induced, acute kainic acid-induced, and chronic temporal lobe epilepsy (pilocarpine). NOR-1202 was administered via intracerebroventricular injection (using stereotaxic surgery), subcutaneous, or intraperitoneal routes at various doses.
Who was studied
Male mice in acute and chronic seizure models (pilocarpine and kainic acid induced)
What this study cannot tell us
Animal study only — no human data. The peptide's inability to work when given systemically is a major limitation for clinical development. Only male mice were used, limiting generalizability. Small sample sizes typical of animal studies. The chronic epilepsy model showed no benefit, raising questions about efficacy in established epilepsy.
How to read the evidence
Rated preliminary: early-stage animal study with a novel compound that only works via direct brain injection. Far from clinical application.
When this study was published
Published in 2024. Very early preclinical research — clinical testing would require solving the systemic delivery problem first.
The bigger picture
Venoms are rich sources of bioactive peptides that evolution has optimized to affect nervous system function. Mining venom peptides for neurological therapeutics is a growing field, though the blood-brain barrier remains a major challenge for peptide drug delivery.
Questions still open
- Can NOR-1202 be modified to cross the blood-brain barrier?
- What is the specific neuronal mechanism by which NOR-1202 prevents seizures?
- Would intranasal delivery bypass the blood-brain barrier limitation?
Common questions
Can wasp venom peptides treat epilepsy?
Why didn't the peptide work when injected under the skin?
Read the original research
Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models.
Toxins, 16(8)
Citation
Quintanilha, Maria Varela Torres; Gobbo, Giovanna de Azevedo Mello; Pinheiro, Gabriela Beserra; Souza, Adolfo Carlos Barros de; Camargo, Luana Cristina; Mortari, Marcia Renata. (2024). Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models.. Toxins, 16(8). https://doi.org/10.3390/toxins16080342